JAVELIN Bladder 100: Phase III Trial of Maintenance Avelumab After First-line Platinum Chemotherapy in Advanced Urothelial Carcinoma

Download this expert slideset on strategies for developing compassionate care plans with transgender patients based on their current anatomy

Lauren Radziejewski, DNP Released: October 4, 2022

Phase III COSMIC-313: addition of cabozantinib to nivolumab plus ipilimumab in previously untreated patients with IMDC intermediate- or poor-risk advanced RCC, presented at ESMO 2022 and reported by Clinical Care Options (CCO)

Phase I/II EV-103 cohort K: enfortumab vedotin with or without pembrolizumab as first-line treatment in cisplatin-ineligible locally advanced urothelial cancer, presented at ESMO and reported by Clinical Care Options (CCO)

CheckMate 274: pretreatment tumor and immune features and DFS with adjuvant nivolumab in high-risk muscle-invasive UC following radical resection, presented at ESMO 2022 and reported by Clinical Care Options (CCO)